No adjuvant therapy | Tamoxifen monotherapy | |||||
---|---|---|---|---|---|---|
Factors | Bcl-2 | P-value | Bcl-2 | P-value | ||
+ (%) | - | + (%) | - | |||
Menopause | 0.0049* | 0.1249 | ||||
Post | 156 (58) | 112 | 191 (64) | 108 | ||
Pre | 210 (70) | 92 | 117 (71) | 48 | ||
Tumor size | 0.0023* | 0.0051* | ||||
>20 mm | 199 (58) | 143 | 178 (61) | 112 | ||
≤20 mm | 204 (70) | 88 | 138 (74) | 49 | ||
Node | 0.9049 | 0.2938 | ||||
+ | 96 (63) | 56 | 141 (64) | 80 | ||
- | 307 (64) | 175 | 175 (68) | 81 | ||
Grade | <0.0001* | 0.0040* | ||||
II + III | 244 (54) | 205 | 170 (61) | 109 | ||
I | 157 (86) | 26 | 145 (74) | 52 | ||
ER | <0.0001* | <0.0001* | ||||
+ | 330 (88) | 45 | 290 (74) | 100 | ||
- | 71 (28) | 186 | 26 (30) | 61 | ||
PR | <0.0001* | <0.0001* | ||||
+ | 242 (89) | 30 | 189 (76) | 59 | ||
- | 159 (44) | 200 | 127 (55) | 102 | ||
HER2 | <0.0001* | 0.0005* | ||||
+ | 19 (21) | 70 | 8 (33) | 16 | ||
- | 381 (70) | 160 | 308 (68) | 145 | ||
Total | 634 | 477 |